Considering MMR status in advanced-stage CRC, BRAF mutation seems to have a negative prognostic role on PFS and OS only in MSS CRC patients, whereas there is no difference in terms of survival between MSI-H/BRAF-mutated and MSI-H/BRAF-WT cancers [29]. This evidence concerns the gene BRAF and colorectal carcinoma.